Objectives: Cytokine receptor-like factor 2 (CRLF2) rearrangement is found in approximately 50% of pediatric Ph-like B-cell acute lymphoblastic leukemia (B-ALL), and around 50% of CRLF2þ cases harbor JAK mutations. We analyzed CRLF2 expression and studied its correlation with CRLF2 rearrangement in adult patients with B-ALL.
Results: CRLF2 overexpression was detected in 30 (27%) patients, 28 (41%) of 69 patients with B-ALL not otherwise specified, 14 (21%) of 67 untreated patients, and 16 (27%) of 59 patients with relapsed B-ALL, with the highest among Hispanic patients (25/55, 45%). Of CRLF2þ cases, 21 (100%) of 21 cases showed CRLF2 rearrangement by fluorescence in situ hybridization, preferentially involving IGH@CRLF2 (15/15). The entire coding region of JAK2 was sequenced in 14 patients with CRLF2þ B-ALL, and nine (64%) were positive for JAK2 mutations.
Conclusions: MFC allows a rapid, inexpensive, and reliable detection of B-ALL with CRLF2 rearrangement that would further facilitate testing for JAK2 mutations for targetable therapy.
Ph-like B-cell acute lymphoblastic leukemia (B-ALL), also known as B-lymphoblastic leukemia/lymphoma, BCR-ABL1-like, is defined by a gene expression profile similar to Philadelphia chromosome-positive B-ALL (Phþ B-ALL) but lacks the rearrangement of t(9;22)(q34;q11;2)/ BCR-ABL1.
1,2 Ph-like B-ALL is characterized by a number of molecular genetic alterations involving various kinase pathways, including ABL class fusions, EPOR/JAK rearrangements, JAK-STAT pathway alterations, RAS mutations, or unknown kinase pathway alterations. 3 Cytokine receptor-like factor 2 (CRLF2), located on chromosome Xp22.3 and Yp11. 3, 4 has been found overexpressed in approximately half of the Ph-like B-ALLs. 5 Overexpression of CRLF2 in B-ALL often results from a cryptic deletion within pseudoautosomal region 1 of the sex chromosomes, which juxtaposes CRLF2 to the P2RY8 promoter (P2RY8-CRLF2) or positions CRLF2 under the control of the immunoglobulin heavy chain gene (IGH@-CRLF2). CRLF2 expression also can be upregulated by gain-of-function mutations either in CRLF2 itself or in its partner gene, IL7RA. CRLF2 overexpression can be assessed by real-time quantitative polymerase chain reaction 6, 7 or flow cytometry methods. 8, 9 Approximately half of CRLF2þ B-ALLs carry JAK (mainly JAK2, rarely JAK1 and JAK3) mutations 4, 5, 10 Ph-like B-ALL represents a group of B-ALLs with an adverse clinical outcome; however, these patients may respond to kinase inhibitor therapy. 5, 11 Patients with JAK mutations may potentially benefit from JAK2 inhibitor ruxolitinib treatment. Most studies addressing Ph-like B-ALL have dealt with pediatric patients. Herold and colleagues 12 reported in a letter that the incidence of Ph-like ALL decreased significantly with advanced age in the German population. Here we report the results of a prospective study at a single institution in adult patients with B-ALL, with the focus on CRLF2 expression and its correlation with CRLF2 rearrangement by fluorescence in situ hybridization (FISH), as well as JAK2 mutation status in a subset of patients.
Materials and Methods

Validation of CRLF2 Expression by Multiparameter Flow Cytometry
With approval of the study from the institutional review board at MD Anderson Cancer Center, we first studied CRLF2 expression by multiparameter flow cytometry (MFC) on fresh-frozen cell suspensions from a group of patients with B-ALL who were known to have a Ph-like signature by gene expression profiling study.
2 MFC (FACSCanto II instruments; BD Biosciences, Mountain View, CA) was performed using phycoerythrin-conjugated anti-CRLF2 antibody (clone eBio1A6; eBioscience, San Diego, CA) with the concentration recommended by the manufacturer, and CRLF2 expression was directly assessed on B lymphoblasts identified by a combination of CD19, CD10, CD34, and CD45 markers (all antibodies purchased from BD Biosciences). Data were analyzed using FCS Express software (De Novo Software, Los Angeles, CA). The validation study also included testing for CRLF2 expression in normal bone marrows (BMs), acute myeloid leukemia (AML), chronic myeloid leukemia (CML), and T-cell lymphoblastic leukemia.
Prospective Flow Cytometry Study
After validation study, CRLF2 expression was analyzed by MFC consecutively in all patients with a diagnosis of B-ALL during a 2-year period. These included patients either with de novo B-ALL or relapsed/refractory B-ALL. BM or peripheral blood samples were incubated with antibodies conjugated with various fluorochromes. A complete immunophenotyping study was performed simultaneously in all patients using a comprehensive panel of antibodies as part of the clinical workup for acute leukemia. A total of 200,000 events per tube were acquired.
FISH and JAK2 Mutation Study
FISH was performed using a dual-color break-apart CRLF2 FISH probe (Cytocell/OGT, Oxfordshire, UK) following the standard method on direct smears or cultured cells. In a subset of cases, CRLF2 metaphase FISH was performed to identify fusion partners. FISH for BCR-ABL1 was performed on interphase nuclei using the Vysis BCR-ABL ES, dual-color, translocation, locus-specific probe (Abbott Molecular, Des Plaines, IL) in all cases. The entire coding region of JAK2 was sequenced using a customized TruSeq Amplicon Cancer Panel and a MiSeq sequencer (illumina, San Diego, CA). The next-generation sequencing (NGS) 13 panel also included ABL1, ASXL1, BRAF, DNMT3A, EGFR, EZH2, FLT3, GATA1, GATA2, HRAS, IDH1, IDH2, KIT, KRAS, MDM2, IKZF2, KMT2A, MPL, MYD88, NOTCH1, NPM1, NRAS, PTPN11, RUNX1, TET2, TP53, and WT1.
Statistical Analysis
For continuous variables, data were reported as median and range. For nominal variables, data were reported as the number of patients unless otherwise specified. Fisher exact and v 2 tests
were used for categorical comparisons. Distribution of overall survival was estimated by Kaplan-Meier curves. All P values were two-tailed and were considered significant when less than .05. No adjustments for multiplicity were made.
Results
Validation Study of CRLF2 Expression by Flow Cytometry
Of the 10 cases proven to have a Ph-like B-ALL gene expression profile, five had a CRLF2 gene rearrangement, all of which showed strong CRLF2 expression in leukemic cells by flow cytometry. The other five B-ALL cases without a CRLF2 rearrangement were negative for CRLF2 expression. We further analyzed an array of patient specimens, including 56 BM samples that were negative for B-ALL but had significant numbers of hematogones (normal precursor B cells), 10 AMLs, three CMLs in B-lymphoblastic crisis, three mixed-phenotype acute leukemias, and two cases of T-cell lymphoblastic leukemia. None of these cases demonstrated any degree of CRLF2 expression.
CRLF2 Expression in Adult B-Lymphoblastic Leukemia/Lymphoma
Between September 2013 and September 2015, we tested consecutively a total of 126 patients with B-ALL by MFC, of whom 67 patients had a newly diagnosed/untreated B-ALL and 59 patients had relapsed/refractory disease. A total of 30 (27%) patients had CRLF2 expression. Of the cases with CRLF2 expression, blasts did not exhibit any unique morphologic features, with cells ranging from small to large and chromatin varying from immature to more mature, which corresponded to French-American-British classification L1 or L2 subtype Image 1 . The expression of CRLF2 on blasts was uniform within each case, but variation in expression intensity was observed between cases Figure 1 . CRLF2 expression frequency was comparable between patients with de novo (14/67, 21%) vs relapsed/ refractory (16/59, 27%) B-ALL Table 1 . Although the numbers were small, the frequency of CRLF2 expression appeared to be more frequent in adolescents aged 18 to 20 years (3/6, 50%) and infrequent among patients older than 55 years (1/9, 11%) (P ¼ .235). The frequencies were comparable between young adults (aged 21-39 years; 17/58, 29%) and adults (aged 40-55 years; 5/19, 26%), respectively. CRLF2 expression was detected in one of seven patients with a hyperdiploidy and one of 35 patients with Phþ B-ALL but not in any of patients with other genetic abnormalities (n ¼ 11). The latter included seven patients with MLL gene rearrangement, three patients with t(1:19)/ TCF3-PBX1, and one patient with t(12;21)/ETV6-RUNX1. In addition, CRLF2 was not detected in any of the four patients with a hypodiploidy.
Of the remaining 69 patients with B-ALL not otherwise specified (NOS), 14 CRLF2 expression was detected in 28 (41%) patients and had a similar frequency between de novo (12/29, 41%) and relapsed/refractory (16/40, 40%) patients. Of interest, CRLF2 expression was significantly more common among Hispanic patients (25/55, 45%) compared with non-Hispanic whites (5/60, 8%) both at the time of diagnosis (48% vs 11%, P < .001) and at the time of relapse (44% vs 4%, P < .001). Surprisingly, we did not find a single patient with CRLF2 expression among Asian (n ¼ 5) or African American (n ¼ 6) patients, although the numbers of patients in these groups were small.
Correlation of CRLF2 Expression by Flow Cytometry With FISH
Interphase FISH was performed in 21 of 30 patients with CRLF2 expression. FISH demonstrated CRLF2 rearrangement in all 21 cases, showing a 100% concordance with the MFC results Table 2 . One case showed both CRLF2 and BCR-ABL1 rearrangements involving 90% and 55% interphases, respectively. Furthermore, CRLF2 metaphase FISH was performed in 15 of the 21 cases and revealed an apparent IGH@CRLF2 fusion Image 2 in all 15 cases. None of the cases showed signs of P2RY8-CRLF2 rearrangement.
JAK2 Mutation in CRLF21 Cases
Mutations in JAK2 along with 27 other genes were tested in 14 patients with CRLF2 expression using NGS technology. JAK2 mutations were detected in nine (64%) of 14 patients with a positive CRLF2 expression. The most common JAK2 mutation was in codon c.2047A > G p.R683G (n ¼ 5), followed by c.2044A > T p.I682F (n ¼ 2), c.1832T > C p.L611S (n ¼ 1), and c.2049A > T p.R683S (n ¼ 1). While this NGS panel was not designed for B-ALL, mutations in other myeloid neoplasm-related genes were frequently detected, including ASXL1 (n¼ 5), KRAS (n ¼ 2), NRAS (n ¼ 2), and RUNX1, TP53, NOTCH, MLL, KIT, and PTPN11 (one each). Only one patient did not show any mutations in the above genes tested. PAX5 and IKZF1 genes were not constructed in the NGS panel, and the mutation status would be of interest to explore in these patients.
Clinical Features and Outcomes of Patients With CRLF2 Expression
The additional details of clinical and laboratory data of patients with CRLF2 expression are presented in the Table  2 . Comparing clinical and laboratory data of patients with de novo B-ALL with CRLF2 expression and de novo Phþ B-ALL, we did not find any statistical difference in age, the degree of leukocytosis, anemia, thrombocytopenia, or percentage of blasts. Although there was a slight male predominance among patients with CRLF2 expression, the difference was not significant.
All newly diagnosed patients received high-dose chemotherapy, and patients with Phþ B-ALL also received a frontline tyrosine kinase inhibitor. For these patients with de novo B-ALL, the follow-up was short (median, 16 months; range, 0-35 months). During the study period, four of 27 Phþ, four of 14 CRLFþ, and six of 20 NOS/hyperdiploidy/ hypodiploidy B-ALL patients underwent hematopoietic stem cell transplantation. While patients with Phþ B-ALL showed a better overall survival (OS) than patients with NOS/ hyperdiploidy or hypodiploidy (P ¼ .018), the OS of patients with CRLF2þ B-ALL (n ¼ 14) was not statistically different from Phþ B-ALL (n ¼ 27) (P ¼ .890) or other B-ALL NOS/ hyperdiploidy/hypodiploidy (n ¼ 20) (P ¼ .177) Figure 2 .
Discussion
Our study demonstrated an overall CRLF2 expression frequency of 27% in adult patients with B-ALL and 41% among patients with a diagnosis of B-ALL NOS. CRLF2 expression frequency appears to be the lowest in patients older than 55 years, although this needs to be further confirmed in large cohort studies. This finding is in keeping with a generally lower frequency of Ph-like B-ALL in the elderly patients reported by Herold and colleagues 12 by gene expression profiling, which likely attributes to a significantly increased incidence of Phþ B-ALL in elderly patients. Similar to what has been observed in pediatric patients, 15 CRLF2 expression is significantly more common In this study, we showed that CRLF2 expression detected by flow cytometry was 100% (21 of 21) concordant with CRLF2 gene rearrangement by FISH. Furthermore, metaphase FISH was performed in 15 patients: all 15 patients showed apparent IGH@CRLF2 rearrangement, and none showed P2RY8-CRLF2. This preferential involvement of the IGH partner gene is in contrast to a significantly more frequent P2RY8-CRLF2þ than IGH@-CRLF2þ in pediatric patients. 18 The difference in CRLF2 fusion partners between pediatric and adult patients is intriguing but unexplained. Although only tested in a subset of patients, we showed that JAK2 was frequently mutated in CRLF2þ B-ALL (9/14, 64%), with a frequency similar to what is reported in pediatric and adolescent patients. 5 Of note, we did not test JAK2 mutation in CRLF2-cases in this study. Although it has been shown in previously published studies 3, 5 Figure 2 Overall survival (OS) comparison of patients who sought treatment for newly diagnosed B-cell acute lymphoblastic leukemia (B-ALL) at our hospital and received highdose chemotherapy, some with stem cell transplant. Patients with Phþ B-ALL also received frontline tyrosine kinase inhibitor. Patients with Phþ B-ALL showed a better OS than patients with not otherwise specified/hyperdiploidy/hypodiploidy B-ALL (P ¼ .018), whereas the OS of patients with cytokine receptor-like factor 2-positive B-ALL (n ¼ 14) was not statistically significant different from either group.
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Image 2 A, B, Metaphase fluorescence in situ hybridization using a dual-color break-apart probe for cytokine receptor-like factor 2 shows an apparent cryptic t(Y;14)/IGH-CRLF2 fusion.
neoplasm-associated genes, similar to that reported in a previous study in pediatric patients. 18 The outcome comparison was attempted but the result was limited by the small number of each subgroup of patients and the short follow-up. Of note, B-ALL with CRLF2 expression has been shown to have different survival by JAK2 mutation status 5 ; however, we did not have a sufficient number of patients to perform this comparison.
In summary, CRLF2 expression is frequent in adult patients with Ph-B-ALL and highly correlated with CRLF2 gene rearrangement. Flow cytometry analysis allows a rapid, inexpensive, and reliable detection of CRLF2 expression. JAK2 is frequently mutated in CRLF2þ B-ALL, and further testing for JAK2 mutation in CRLF2-overexpressed samples can identify patients who may potentially benefit from JAK2 inhibitor therapy. While Ph-like B-ALL and B-ALL with recurrent cytogenetic abnormalities were previously considered to be mutually exclusive, our observation of a patient with both CRLF2 and BCR-ABL1 rearrangements indicates that rare exceptions do exist.
